SCHEMBL7202583

SCHEMBL7202583

O=C(NO)C1(O)CNCCC1S(=O)(=O)N1CCC(OCc2ccccn2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 1/20 0.40
GAA P10253 3/20 0.39
KMT2A Q03164 2/20 0.39
TSHR P16473 2/20 0.39
MEN1 O00255 1/20 0.39
MMP13 P45452 3/20 0.38
MMP14 P50281 2/20 0.38
DRD4 P21917 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
LPL P06858 1/20 0.38
LIPC P11150 1/20 0.38
LIPG Q9Y5X9 1/20 0.38
MMP2 P08253 2/20 0.37
PKM P14618 2/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
USP2 O75604 1/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7200956 0.86 MMP2 (0.46) ADAM17MMP13SIGMAR1MMP2MMP1
SCHEMBL7204219 0.85 MMP13 (0.48) MMP13MMP14MMP2MMP1MMP3
SCHEMBL7200602 0.84 EPHX2 (0.41) ADAM17MMP13MMP2MMP1
SCHEMBL7207005 0.84 MMP13 (0.42) ADAM17MMP13MMP14MMP2MMP1
SCHEMBL7201714 0.83 CHRM2 (0.43) KMT2ATSHRMMP13MMP14MMP2
SCHEMBL7208003 0.83 ALDH1A1 (0.41) ADAM17KMT2ATSHRMEN1MMP13
SCHEMBL7205353 0.83 CARM1 (0.42) ADAM17MMP13MMP2PKMMMP1
SCHEMBL7200507 0.83 MMP13 (0.45) ADAM17GAAKMT2AMEN1MMP13
SCHEMBL7205529 0.83 MMP1 (0.45) ADAM17MMP13MMP2MMP1
SCHEMBL7201688 0.81 MMP13 (0.43) ADAM17MMP13MMP14LIPGMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 ADAM17 162/4885GAA 131/4885KMT2A 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.